FDA approves glucose monitoring system

The Food and Drug Administration recently approved the FreeStyle Libre Flash Glucose Monitoring System to be sold in the United States. The Libre is manufactured by Abbott and is currently only available overseas. The system allows patients to view blood sugar every minute of the day without pricking a finger. The device will be available […]

#1 Cause of Vision Loss in Adults? Diabetes.

Diabetic retinopathy is the #1 cause of vision loss among working adults between the ages of 20 and 74 in the United States.* Lucentis recently gained FDA approval for monthly treatment of every form of diabetic retinopathy. This marks the first drug that the FDA has approved to treat diabetic retinopathy “with or without diabetic macular […]

App allows users to ‘see’ retinal disease

A new virtual and augmented reality app called “In My Eyes” allows users to experience what it is like to have different kinds of retinal disease. Regeneron Pharmaceuticals teamed with Intouch Solutions to create the app. Available for free download in the iTunes and Google app stores, the app can be used with or without […]

Diabetics more likely to skip eye exams

Despite having a higher risk of developing serious eye diseases that could potentially rob them of their vision, nearly 60 percent of diabetics do not have yearly eye exams. Diabetics are at a greater risk of losing their vision to diabetic retinopathy and the disease can lead to additional blinding eye problems if not caught early and […]

Eylea effective for Diabetic Retinopathy

A two-year clinical trial has found that diabetic patients suffering from severe vision loss from diabetic macular edema benefit the most from receiving treatment with Eylea versus Avastin or Lucentis. Eylea was just approved for use by the FDA for treating diabetic macular edema patients last year. The study was conducted by the National Institutes […]

Lucentis beats lasers in treating diabetic retinopathy

A study funded by the National Eye Institute determined that Lucentis injections trumped laser therapy in treating proliferative diabetic retinopathy. The study results were published in the Journal of the American Medical Association online. 305 patients were included in the study with half of them receiving monthly Lucentis injections for three months and then only […]

Endophthalmitis risk greater with intravitreal steroid injections

Endophthalmitis, an inflammation of the internal eye, is a possible complication with any intraocular procedure including intravitreal steroid injections and anti-VEGF injections. A new study found that the risk for developing endophthalmitis after intravitreal steroid injections is nearly seven times greater than the risk after anti-VEGF injections. Prior to the advent of anti-VEGF injections, intravitreal […]

Eylea approved as diabetic retinopathy treatment

The FDA gave its approval for Eylea to be used in the treatment of diabetic retinopathy in patients with diabetic macular edema. Currently one third of diabetic patients over the age of 40 have some variation of the eye disease. Diabetic retinopathy with macular edema can cause abnormal blood vessels to form on the retina’s […]

Avastin more effective for diabetic macular edema

A recent study did a comparison of the three top drugs used to treat diabetic macular edema. Researchers took a look at Avastin, Eylea and Lucentis and while all three drugs were equally effective in improving vision in patients who had slight vision impairment, Eylea was found to be more effective in treating patients with […]

Lucentis gains FDA approval for treating diabetic retinopathy

Earlier this month, the FDA expanded the approved use of Lucentis to include its use in treating diabetic retinopathy in people who have diabetic macular edema. The announcement came after two clinical studies confirmed the drug’s safety and efficacy in treating diabetic retinopathy in diabetic macular edema patients. Patients involved in the study who received […]